Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients

Journal of the American College of Cardiology

Volumn 56, Issue 14, 2010, Pages 1079-1088

  Rosenson, Robert S ^a   Hislop, Colin ^b   Elliott, Michael ^b   Stasiv, Yuri ^b   Goulder, Michael ^c   Waters, David ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Anthera Pharmaceuticals   (United States)

^c Worldwide Clinical Trials   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

acute coronary syndromes; inflammation; low density lipoprotein; secretory phospholipase A2; varespladib

Indexed keywords

A 001; A 002; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOLYTIC AGENT; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LY 333013; PLACEBO; PRAVASTATIN; PRODRUG; S 3013; SECRETORY PHOSPHOLIPASE A2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VARESPLADIB; VARESPLADIB METHYL; VERY LOW DENSITY LIPOPROTEIN; ACETIC ACID DERIVATIVE; HEPTANOIC ACID DERIVATIVE; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANGINA PECTORIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ATHEROGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; LIVER FUNCTION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; UNSTABLE ANGINA PECTORIS; BLOOD; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; REFERENCE VALUE; STATISTICAL MODEL; TREATMENT OUTCOME;

ACETATES; ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; INDOLES; LOGISTIC MODELS; MALE; MIDDLE AGED; PHOSPHOLIPASES A2, SECRETORY; PROSPECTIVE STUDIES; PYRROLES; REFERENCE VALUES; TREATMENT OUTCOME;

EID: 77956571375     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.06.015     Document Type: Article

References (42)

1. J.L. Anderson, C.D. Adams, and E.M. Antman ACC/AHA 2007 guidelines for the management of patients with unstable angina/nonST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/NonST-Elevation Myocardial Infarction) J Am Coll Cardiol 50 2007 e1 e157
2. S.M. Grundy, J.I. Cleeman, C.N. Merz National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239 (Pubitemid 38924592)
3. P.M. Ridker, C.P. Cannon, D. Morrow Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
4. J. Zacho, A. Tybjaerg-Hansen, J.S. Jensen, P. Grande, H. Sillesen, and B.G. Nordestgaard Genetically elevated C-reactive protein and ischemic vascular disease N Engl J Med 359 2008 1897 1908
5. T. Koike, S. Kitajima, and Y. Yu Human C-reactive protein does not promote atherosclerosis in transgenic rabbits Circulation 120 2009 2036 2039
6. J. Danesh, and M.B. Pepys C-reactive protein and coronary disease: is there a causal link? Circulation 120 2009 2088 2094
7. 2 inhibitors in the prevention of atherosclerotic cardiovascular disease Cardiovasc Drugs Ther 23 2009 93 101
8. 2: a multifaceted family of proatherogenic enzymes Curr Cardiol Rep 11 2009 445 451
9. 2s in human atherosclerosis development Atherosclerosis 196 2008 81 91
10. 2 in culprit coronary lesions is associated with myocardial infarction Eur J Clin Invest 38 2008 205 210
11. 2 increases atherosclerotic lesion formation in LDL receptor-deficient mice Arterioscler Thromb Vasc Biol 23 2003 263 268
12. 2 promotes atherosclerosis: evidence from genetically altered mice Arterioscler Thromb Vasc Biol 27 2007 600 606
13. 2 predict coronary events in patients with coronary artery disease Circulation 100 1999 1280 1284 (Pubitemid 29440119)
14. 2 in patients with coronary artery disease undergoing percutaneous coronary intervention Eur Heart J 24 2003 1824 1832
15. 2 in patients with unstable angina pectoris Am J Cardiol 86 2000 718 722
16. 2 in prediction of the prognosis of patients with suspected myocardial infarction Basic Res Cardiol 95 2000 413 417
17. 2 activity and risk of incident coronary events in healthy men and women: the EPIC-NORFOLK study Arterioscler Thromb Vasc Biol 27 2007 1177 1183
18. 2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease Eur Heart J 30 2009 2742 2748
19. 2 on low density lipoproteins and inflammatory pathways Lancet 373 2009 649 658
20. 2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease Eur Heart J 2010 In press
21. 2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE/ mice J Cardiovasc Pharmacol 53 2009 60 65
22. 2 inhibitor varespladib (A-002) J Lipid Res 50 2008 623 629
23. 2 alters the expression of selected ApoB-100 epitopes and the interaction of LDL with cells J Lipid Res 29 1988 729 743
24. 2 results in accelerated atherogenesis by increasing oxidative stress J Lipid Res 46 2005 1604 1614
25. C. Flood, M. Gustafsson, and R.E. Pitas Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100 Arterioscler Thromb Vasc Biol 24 2004 564 570
26. 2 in normal and atherosclerotic arteries: activity of the isolated enzyme on low-density lipoproteins Arterioscler Thromb Vasc Biol 17 1997 300 309
27. 2 modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans J Biol Chem 274 1999 25913 25920
28. 2 induces particle fusion and enhances the retention of LDL to human aortic proteoglycans Arterioscler Thromb Vasc Biol 21 2001 1053 1058
29. 2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation Arterioscler Thromb Vasc Biol 24 2004 762 767
30. 2 is linked to macrophage foam cell formation J Biol Chem 277 2002 29116 29124
31. 2 in atherosclerosis: 2 Potential involvement of biologically active oxidized phospholipids Arterioscler Thromb Vasc Biol 19 1999 1291 1298
32. 2 involved in arachidonic acid mobilization in murine P388D1 macrophages J Biol Chem 271 1996 32381 32384
33. 2 J Biol Chem 277 2002 36479 36488
34. 2 in allergen-induced airway inflammation and remodeling in a mouse asthma model J Exp Med 204 2007 865 877
35. 2 generation in mouse bone marrow-derived mast cells J Biol Chem 271 1996 25936 25944
36. 2 but not the group Ib, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells J Biol Chem 275 2000 3179 3191
37. 2 type IIA binds to integrins alpha V beta 3 and alpha 4 beta 1 and induces proliferation of monocytic cells in an integrin-dependent manner J Biol Chem 283 2008 26107 26115
38. D.A. Morrow, J.A. de Lemos, and M.S. Sabatine Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor trial Circulation 114 2006 281 288
39. A. Jahangiri, M.C. de Beer, and V. Noffsinger HDL remodeling during the acute phase response Arterioscler Thromb Vasc Biol 29 2009 261 267
40. 2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study J Am Coll Cardiol 51 2008 1632 1641
41. P.W. Serruys, H.M. Garca-Garca, P. Buszman Integrated Biomarker and Imaging Study-2 Investigators Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque Circulation 118 2008 1172 1182
42. 2 Annu Rev Biochem 77 2008 495 520